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Healthy Adults
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Karen Stern, Christa L. Stoughton, Daniel Wollin, Michael Borofsky, Naeem Bhojani,
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OBJECTIVE
MATERIALS AND
METHODS

RESULTS

CONCLUSION

To assess the effect of 2 over-the-counter alkalizing agents on 24 hour urinary parameters.
Ten healthy volunteers without a history of kidney stones were recruited to complete a baseline
24 hour urinalysis with a 4 day diet inventory. Participants then maintained the same diet on
either LithoLyte (20 mEq 2 times per day) or KSPtabs (1 tablet 2 times per day) and submitted
another 24 hour urinalysis. The process was repeated with the other supplement. Urinary alkali
parameters were compared to baseline, and side effects were elicited with a questionnaire.
LithoLyte intake resulted in a non-signiﬁcant increase in citrate (597-758 mg/day, P =.058, an
increase in urine pH (6.46-6.66, P =.028), and a decrease in urine ammonium (41-36 mmol/day,
P =.005) compared to baseline. KSPtabs resulted in an increase in citrate (597-797 mg/day, P
=.037) and urine pH (6.46-6.86, P =.037), with a non-signiﬁcant decrease in ammonium (4134 mmol/day, P =.059). No signiﬁcant differences were seen comparing urinary analytes between
LithoLyte and KSPtabs. With Litholyte, no side effects, mild, moderate, and severe side effects
were seen in 50%, 40%, 10%, and 0%, respectively. With KSPtabs, rates were 60%, 20%, 10%,
and 10%, respectively.
In healthy participants without a history of kidney stones, LithoLyte and KSPtabs are effective
over-the-counter alkali supplements, with a similar side effect proﬁle to prescription potassium citrate. UROLOGY 00: 1−7, 2022. © 2022 Elsevier Inc.

U

rinary citrate is a potent inhibitor of kidney
stones1; hypocitraturia is a common abnormality
in the recurrent stone former.2 The American
Urological Association (AUA) guidelines speciﬁcally recommend potassium citrate for urinary alkalization in
hypocitraturic calcium stone formers, uric acid stone
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formers and cystine stone formers.3 This is based on the
signiﬁcant improvement in urinary parameters, and the
reduced risk of recurrent stone disease.4
However, there is poor adherence to prescribed potassium citrate therapy.5 Some patients experience signiﬁcant gastrointestinal side effects that preclude their ability
to tolerate the medication.6 In addition, the cost of prescription potassium citrate, as well as the size of the pills,
can be prohibitive for some patients.
More recently, patients have had increased access to
alternative over-the-counter alkali preparations.7 These
typically contain various combinations of both sodium
and potassium alkali salts, although the efﬁcacy of these
supplements is unknown. Our goal was to assess the effect
of two over-the-counter alkalizing agents on 24 hour urinary parameters in healthy adults without a history of kidney stones.

MATERIALS AND METHODS
We performed a prospective crossover study of 2 over-the
counter alkali supplements used to raise urine pH and citrate
https://doi.org/10.1016/j.urology.2022.05.049
0090-4295
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excretion. Institutional Review Board approval was obtained
prior to study initiation (Vanderbilt IRB 191141). A total of 10
healthy adults without a history of kidney stone disease were
recruited and informed consent was obtained.
Over-The-Counter Supplements
The following two supplements were chosen based on the most
frequent over-the-counter alkalizing supplements taken by
patients, as determined in our previous review.7
LithoLyte (Trent Woods, North Carolina) is a ﬂavorless powder containing potassium citrate (200 mg = 4.5 mEq), magnesium citrate (30 mg = 2.5 mEq), and sodium bicarbonate (60
mg = 3.5 mEq), and is formulated as individual 10 mEq packets.
Participants dissolved 2 packets in 16 oz of water and ingested
2 times per day per manufacturer recommendations.
KSPtabs (Austin, Texas) are effervescent tablets that contain
vitamin B6 (7.5 mg), magnesium citrate/oxide (64 mg = 5 mEq),
sodium bicarbonate and/or carbonate (170 mg = 5 mEq), and
potassium citrate and/or bicarbonate (160 mg = 5 mEq), for a
total of 15 mEq alkali per tablet. Each tablet is dissolved in 16 oz
of water and ingested 2 or 3 times per day per manufacturer recommendations. For this study, participants consumed 1 tablet
2 times per day.
We maintained "2 times per day” to be consistent with supplement consumption despite different alkali doses, given potential inconsistency with a mid-day third dose.
24 Hour Urine Collections
Participants collected a total of three 24 hour urine collections
and controlled their own diet throughout the study. While completing a diet inventory for 4 days, each participant collected a
baseline 24 hour urinalysis (Urine 1) starting at day 4. Then,
after a minimum 3 day washout period, participants were randomized 1:1 to start either LithoLyte or KSPtabs following the
same diet inventory, and collected another 24 hour urinalysis
starting at day 4 (Urine 2). After another washout of at least
3 days, the process was repeated with the other supplement
(Urine 3). All 24 hour urine collections were performed at-

home and analyzed through Litholink Corporation (LabCorp,
Chicago, IL). Participants were blinded to the results of each
collection until after study completion.
Adverse Events
Adverse events were assessed based on Common Terminology
Criteria for Adverse Events v5.0,8 with a focus on general and
gastrointestinal disorders. Participants were provided an adverse
event survey to complete after taking each supplement. Additionally, participants were asked whether or not they would be
willing to tolerate long-term intake of the supplement.
Statistical Analysis
Statistical analysis was performed using IBM SPSS version 22
(Armonk, New York). Each participant’s urinary creatinine values were compared between the three collections to determine
the coefﬁcient of variation. Urinalysis median values of alkalization metrics (urinary citrate, pH, ammonium, sodium and potassium) were calculated among the 10 participants for each
collection: baseline, LithoLyte, and KSPtabs. Values were compared between baseline and LithoLyte, baseline and KSPtabs,
and LithoLyte and KSPtabs, using the Wilcoxon Signed Rank
test. Statistical signiﬁcance levels were set at P <.05.

RESULTS
There were 6 male and 4 female subjects with no prior kidney
stone history, a mean age of 37 years, and mean body mass index
of 23.1 kg/m2. The mean coefﬁcient of variation for urine creatinine was 9.2% (standard deviation 4.3%). No participant withdrew from the study.
Table 1 demonstrates median 24 hour urine values during
baseline collections, and while participants ingested LithoLyte
and KSPtabs. Compared to baseline, while participants consumed Litholyte there was an increase in urine pH (6.46-6.66, P
=.028), and a decrease in urine ammonium (41-36 mmol/day, P
=.005) (Fig. 1). A non-signiﬁcant increase in citrate (597758 mg/day, P =.058) and potassium (79-97 mmol/day, P =.09),

Table 1. Median 24 hour urinalyses values from baseline, LithoLyte, and KSPtabs collections.
Baseline
Volume (L)
SS CaOx
Calcium (mg)
Oxalate (mg)
Citrate (mg)
SS CaPhos
pH
SS Uric Acid
Uric Acid (mg)
Sodium (mmol)
Potassium (mmol)
Magnesium (mg)
Phosphorus (mg)
Ammonium (mmol)
Sulfate (mEq)
Urine Urea Nitrogen (g)
Urine Creatinine (mg)

LithoLyte

KSPtabs

Median

IQR

Median

IQR

P value

Median

IQR

P value

2.42
4.40
193
37
597
1.05
6.46
0.28
698
159
79
117
817
41
46
12
1603

1.68-2.88
3.06-6.50
78-240
30-46
496-833
0.26-1.52
5.96-6.80
0.11-0.86
586-743
116-178
55-105
103-144
712-1287
37-48
33-54
11-14
1334-1974

2.73
3.45
171
38
758
0.90
6.66
0.11
659
131
97
130
871
36
47
13
1620

2.06-3.58
1.89-4.67
43-210
28-52
479-1116
0.29-1.39
6.53-7.03
0.08-0.18
488-825
106-187
52-141
114-158
778-1077
27-41
38-58
11-15
1433-2245

0.059
0.005
0.2
0.2
0.058
0.1
0.028
0.017
0.9
1.0
0.09
0.1
0.9
0.005
0.3
0.2
0.6

2.27
3.39
120
40.0
797
0.99
6.86
0.09
675
140
80
126
886
34
42
11
1624

1.75-3.05
1.76-4.78
55-237
30-56
606-959
0.41-1.80
6.59-7.01
0.06-0.19
533-897
114-194
55-140
95-160
605-1065
24-41
31-58
9-14
1297-2265

0.4
0.037
0.009
0.5
0.037
0.8
0.037
0.028
0.5
0.9
0.4
0.9
0.5
0.059
0.5
0.3
0.7

IQR, interquartile range; SS, supersaturation; CaOx, calcium oxalate; CaPhos, calcium phosphate.
P value represents comparison to baseline.
Boldface indicates level of significance (P < 0.05).
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Figure 1. Changes in urine parameters based on alkali supplement. * denotes P <.05 compared to baseline. Error bars represent interquartile ranges.

and a non-signiﬁcant decrease in calcium (193-171 mg/day, P
=.2) were noted.
Compared to baseline, when participants consumed KSPtabs,
an increase was seen in citrate (597-797 mg/day, P =.037), urine
pH (6.46-6.86, P =.037) (Fig. 1), and a decrease in calcium
(193-120 mg/day, P =.009). A non-signiﬁcant decrease in
ammonium (41-34 mmol/day, P =.059) and stable potassium
levels (79-80 mmol/day, P =.4) were also noted. No signiﬁcant
differences were seen comparing urinary analytes between LithoLyte and KSPtabs supplements (all P >.09). Signiﬁcant improvements in supersaturation of calcium oxalate (SS CaOx) and uric
acid (SS Uric Acid) were seen with both supplements.
Side effects were reported with both supplements (Table 2).
With LithoLyte, 5 (50%) participants had no general or gastrointestinal side effects. Mild side effects were reported in 4 (40%)
participants, the most common being diarrhea, dyspepsia, and
bloating. One participant (10%) had moderate side effects with
cramping, bloating, and abdominal pain. No participants experienced severe side effects or stopped Litholyte supplementation
early. Overall, 3 participants (30%) either disagreed or strongly
disagreed with the scenario of having to take LithoLyte indeﬁnitely, while the remaining 7 participants (70%) were neutral or
agreeable. With KSPtabs, 6 participants (60%) noted no general

or gastrointestinal side effects. Two (20%) participants had mild
symptoms, most commonly abdominal distension, diarrhea, and
dyspepsia. One participant (10%) had moderate bloating, and 1
(10%) had severe abdominal cramping. No participants stopped
KSPtabs supplementation early. Overall, 3 participants (30%)
disagreed or strongly disagreed with theoretically taking KSPtabs
indeﬁnitely, while the remaining 7 (70%) were neutral or agreeable.

DISCUSSION
In this prospective study of over-the-counter LithoLyte
and KSPtabs supplementation, we demonstrated 24 hour
urine parameter improvements attributable to an
increased alkali load. Speciﬁcally, LithoLyte was associated with a signiﬁcant increase in urinary pH and a
decrease in urinary ammonia, while KSPtabs was associated with a signiﬁcant increase in urinary citrate and urinary pH, and a decrease in urinary calcium. As a result,
both supplements showed signiﬁcant improvements in SS
CaOx and SS Uric Acid.

Table 2. Side-effect profile of LithoLyte and KSPtabs.
LithoLyte
Abdominal Distention
Abdominal Pain
Belching
Bloating
Constipation
Cramping
Diarrhea
Dysgeusia
Dyspepsia
Nausea
Vomiting
Fatigue
Fever
Malaise
Allergic Reaction

KSPtabs

Mild

Moderate

Severe

Mild

Moderate

Severe

1
0
1
2
0
1
3
0
3
0
0
0
0
1
0

0
1
0
1
0
1
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2
0
1
1
0
1
2
0
2
1
0
0
0
1
0

0
1
0
2
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
1
0
0
0
0
0
0
0
0
0

Values represent the number of participants who experienced the various side effects at the listed severity. Shaded areas were not an
option on the survey.

UROLOGY 00 (00), 2022
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on August 31, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

3

ARTICLE IN PRESS
Urinary citrate is a potent inhibitor of calcium stone
formation by directly complexing with calcium, and by
binding to the calcium oxalate surface to prevent crystal
agglomeration.1 While citrate is freely circulating in
serum, the quantity of urinary citrate is a direct reﬂection
of one’s acid-base status. With acidosis or acid loads, citrate is preferentially reabsorbed from the urine in its divalent form. With alkali loads, citrate is in a trivalent form
and not able to be reabsorbed, hence higher excretion via
the urine.9
Ingestible alkali is critically important for kidney stone
prevention in hypocitraturic calcium stone formers.
When given potassium citrate, they have a 75% risk
reduction of stone recurrence.4 While the AUA guidelines speciﬁcally recommend potassium citrate, only 8%10% of ingested potassium citrate is believed to be directly
excreted as non-metabolized in vivo citrate. Most is converted to bicarbonate via the citric acid cycle.10 Therefore, other alkali salts could be considered in patients who
do not want or cannot tolerate potassium citrate.
There are 4 prospective, randomized, placebo controlled trials of alkali citrate that are routinely cited in
guidelines3 and systematic reviews.4 Although all of these
studies were performed in patients with kidney stones,
there is notable variation in urinary citate improvement
likely due to different alkali salts, doses, and baseline urinary citrate levels.6,11-13 Ettinger et al. gave potassium
magnesium citrate 63 mEq to recurrent calcium oxalate
stone formers for 3 years, and reported a 31% increase in
urinary citrate from 587 to 769 mg/day (P <.05).6 Their
baseline urinary citrate levels were most consistent with
our baseline of 597 mg/day. Similarly, 27% and 34%
improvements were seen with LithoLyte (597-758 mg/day,
P =.06) and KSPtabs (597-797 mg/day, P =.04), respectively. It is conceivable that these effects are dose-dependent, and that higher doses may result in greater
improvement.
The remaining 3 studies all had lower baseline urinary
citrate levels ranging from 235 to 365 mg/day, with more
prominent increases in the treatment arms. Barcelo et al.
gave hypocitraturic calcium stone formers a mean of
potassium citrate 45 mEq, and reported a 74% increase
from 365 to 634 mg/day.11 In 39 patients given potassium
sodium citrate 81 mEq, urinary citrate increased 56% from
259 to 405 mg/day(P =.007).12 And in 46 patients given
potassium citrate 60 mEq/day, hypocitraturic patients
increased 123% from 235 to 525 mg/day, and normocitraturic patients increased 109% from 344 to 719 mg/day.13
Prior animal studies have demonstrated a hypocalciuric
effect while taking potassium citrate.14 This is hypothesized due to direct binding of intestinal and urinary calcium, and indirectly overtime through decreased bone
resorption and increased renal calcium reabsorption.
However, this effect in the previously mentioned alkali
trials was not seen. Ettinger and colleagues showed no signiﬁcant improvement in urinary calcium when given
potassium magnesium citrate (237 mg-225 mg, P >.05),6
while the remaining studies did not report calcium
4

values.11-13 In our study, both LithoLyte and KSPtabs supplementation decreased urinary calcium (193 mg-171 mg
and 120 mg, respectively), but only KSPtabs showed signiﬁcant improvement (P =.009). This could be due to the
higher urinary citrate levels (797 mg), which is greater
than any of the previously mentioned alkali trials.
Alkali loading is also beneﬁcial for uric acid and cystine
stone formers.3 Uric acid crystal solubility is pH sensitive;
urine pH less than the pKa of 5.35 increases crystallization, while urine pH above the pKa increases solubility.15
Cystine has a pKa of 8.3,16 and while increasing urine pH
above that level is not pharmacologically possible, a
higher urine pH of 7.0-7.5 is beneﬁcial to reduce cystine
crystallization. 17 Both LithoLyte and KSPtabs demonstrated a signiﬁcant increase in urine pH from 6.46 to 6.66
(P =.03) and 6.86 (P =.04), respectively. This is consistent with the increase in urine pH from the previously
noted studies from Ettinger et al. (6.01-6.29, P =.08)6 and
Barcelo et al. (5.4-6.4).11 Additionally, effective supplemental alkali should reduce renal ammoniagenesis. Participants had a signiﬁcant decrease in urine ammonium with
LithoLyte (41.4-36.2 mmol/day, P =.005), and a non-signiﬁcant decrease with KSPtabs (41.4-34.4 mmol/day, P
=.06). This has also been previously reported to occur
with potassium magnesium citrate by Ettinger and colleagues (38-28 mmol/day, P <.001).6
There are concerns regarding patient adherence to prescription alkali therapy. Reasons for stopping the medication can include side effects, cost, and/or pill size. In a
retrospective study of 52 patients prescribed sodium potassium citrate over 5.6 years, only 62% consistently took
their medication.5 Similarly, Barcelo and colleagues noted
only 58% of patients were compliant with the potassium
citrate regimen.11 In our short-term study in a small
cohort, 70% of participants were neutral or agreed with
continuing either LithoLyte or KSPtabs, indeﬁnitely. It
should be noted, however, that these were healthy volunteers and incentive to continue the supplementation may
be higher in patients treating stone disease.
Patients are routinely counseled on the known risks of
gastrointestinal side effects with prescription alkali citrate.
Barcelo and colleagues reported mild nausea, epigastric
pain, or abdominal distension in 17% (3/18) of patients
who consistently took the medication.11 Ettinger et al.
reported that 42% of patients had new or worsening gastrointestinal symptoms, with 26% noting these were more
than just slight changes.6 Similarly, in our short-term
study, up to 40% of participants noted bothersome side
effects with either supplement. While long-term tolerability is unknown, this likely reﬂects that many forms of supplemental alkali, when given in sufﬁcient quantities, can
cause gastrointestinal discomfort in a notable percentage
of patients.
Higher socioeconomic status has been associated with
medication adherence,18 perhaps due to the upfront cost
of the medication. Prescription potassium citrate can be
prohibitively expensive for some patients. LithoLyte costs
approximately $2.00/day for a 40 mEq dose, while
UROLOGY 00 (00), 2022
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KSPtabs is approximately $2.60-$3.90/day depending on
the daily dose. Both of these can be upwards of a 50% savings compared to prescription potassium citrate based on a
patient’s prescription drug plan and copays.7
Although less common, the size of prescription potassium citrate pills can be problematic for some patients.
Ettinger et al. reporting that 11% of patients stopped the
study due to inability to swallow the large pills.6 Both liquid and effervescent forms of prescription alkali can be
challenging to ﬁnd and potentially even more expensive.
This could make either LithoLyte and KSPtabs more
appealing.
Our study has multiple limitations that are worth noting. First, this was performed in healthy adults without
known kidney stone history. While these ﬁndings may
not be generalizable to those with kidney stone disease or
those speciﬁcally with hypocitraturia, based on the supplements’ mechanism of action there is likely similar beneﬁt.
Second, the efﬁcacy of these supplements on stone recurrence is unknown. Third, participants maintained their
own diets as controls. Although consistency was shown
between collections, this is inherently less rigorous than a
strict consistent metabolic research diet. Fourth, participants were not blinded to the type of supplement they
were taking. This could introduce bias regarding side
effects and/or dietary changes. Lastly, the sample size may
have been insufﬁcient to detect statistically signiﬁcant differences in all of the urine parameters.
These limitations notwithstanding, we have shown that
over-the-counter LithoLyte and KSPtabs are effective
alkali supplements in a small cohort of healthy adults.
Tolerability appears similar to prescription potassium citrate; patients given these supplements should still be
closely monitored for side effects. Further study in a stone
forming population is warranted to assess the impact on
urinary parameters, as well as potential reduction in stone
recurrence.

CONCLUSION
Over-the-counter LithoLyte and KSPtabs are effective
alkali supplements, with a similar side effect proﬁle to prescription potassium citrate. These supplements could be a
better option for patients with recurrent kidney stone disease who cannot afford or tolerate prescription medications, or desire an over-the-counter alternative to
pharmacologic preventative therapy.
ACKNOWLEDGMENT. We would like to thank Dr. John
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this project.
References
1. Ryall RL. Urinary inhibitors of calcium oxalate crystallization and
their potential role in stone formation. World J Urol. 1997;15:155–
164.
2. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and
medical management. Rev Urol. 2009;11:134–144.

3. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management
of kidney stones: AUA guideline. J Urol. 2014;192:316–324.
4. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an
American College of Physicians Clinical Guideline. Ann Intern
Med. 2013;158:535–543.
5. Jendle-Bengten C, Tiselius HG. Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J
Urol Nephrol. 2000;34:36–41.
6. Ettinger B, Pak CY, Citron JT, et al. Potassium-magnesium citrate is
an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158:2069–2073.
7. Stern KL, Canvasser N, Borofsky M, et al. Alkalinizing agents: A
review of prescription, over-the-counter, and medical food supplements. J Endourol. 2020;34:1–6.
8. National Cancer Institute: Common Terminology Criteria for
Adverse Events (CTCAE). 2018: 1−155. Available at: https://ctep.
cancer.gov/protocolDevelopment/electronic_applications/ctc.htm,
accessed July 12, 2020.
9. Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic
nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31:885−93−
viii.
10. Sakhaee K, Alpern R, Poindexter J, et al. Citraturic response to oral
citric acid load. J Urol. 1992;147:975–976.
11. Barcelo P, Wuhl O, Servitge E, et al. Randomized double-blind
study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993;150:1761–1764.
12. Lojanapiwat B, Tanthanuch M, Pripathanont C, et al. Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. Int Braz J Urol. 2011;
37:611–616.
13. Soyg€ur T, Akbay A, K€upeli S. Effect of potassium citrate therapy on
stone recurrence and residual fragments after shockwave lithotripsy
in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol. 2002;16:149–152.
14. Krieger NS, Asplin JR, Frick KK, et al. Effect of potassium citrate on
calcium phosphate stones in a model of hypercalciuria. J Am Soc
Nephrol. 2015;26:3001–3008.
15. Maalouf NM, Cameron MA, Moe OW, et al. Novel insights into
the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol
Hypertens. 2004;13:181–189.
16. Shekarriz B, Stoller ML. Cystinuria and other noncalcareous calculi.
Endocrinol Metab Clin North Am. 2002;31:951–977.
17. Eisner BH, Goldfarb DS, Baum MA, et al. Evaluation and medical
management of patients with cystine nephrolithiasis: a consensus
statement. J Endourol. 2020;34:1103–1110.
18. Dauw CA, Yi Y, Bierlein MJ, et al. Factors associated with preventive pharmacological therapy adherence among patients with kidney
stones. Urology. 2016;93:45–49.

EDITORIAL COMMENT
In 1985, potassium citrate was approved by the FDA for kidney
stone prevention in distal renal tubular acidosis with calcium
stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology and uric acid lithiasis with or without calcium stones.
Potassium citrate is now widely used either alone or in combination with thiazide or thiazide analogue diuretics for the treatment of calcium nephrolithiasis.
In this issue of Urology, Dr. Canvasser et al. 1 compare the
effects of 2 over-the-counter alkali agents LithoLyte and
KSPtabs effects on the urine alkalinity as well as urinary acid
base proﬁles. The purpose of this study to show the less expensive over-the-counter alkali treatment would be as effective as
the more expensive available potassium tablet, which is commonly used in clinical practice.
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Over all, this study is well done; however, a strong conclusion
will not be drawn given the lack of rigid dietary control and a
small number of studied subjects. Due to the latter circumstances, the lack of signiﬁcant increase in urinary citrate despite a signiﬁcant rise in urinary pH, and a signiﬁcant fall in urinary
ammonium with LithoLyte, and conversely, the effect of
KSPtabs in a signiﬁcant rise in urinary citrate and urinary pH
without a signiﬁcant fall in urinary ammonium could not be fully
explained.
The heterogeneous biochemical response with these 2 alkali
preparations to a major extent is due to different amount of alkali
delivered by 2 products. The alkali delivered by the 2 preparations differed by 9.5 mEq/day. Therefore, this difference in addition to lack of dietary control and a small sample size, have
greatly affected the result and requires to be fully investigated in
the future. Moreover, urinary potassium with both LithoLyte and
KSPtabs, did not change signiﬁcantly suggestive of either lack of
compliance to the drug or due to diarrhea loss of potassium.
With regard to the side effects, both these preparations as well
as previous studies in recurrent calcium oxalate stone formers by
Ettinger et al. 2 and by Barcelo, et al in hypocitraturic calcium
stone former, 3 showed similar minor gastrointestinal side effects
including mild nausea, epigastric pain or abdominal distension.
Although the dosage of alkali used in Ettinger and Barcelo studies
was higher than this study 1 using 63 mEq/day of potassium magnesium citrate and 45 mEq/day potassium citrate, respectively.
Thereby, no deﬁnitive conclusion can be made with the present
study that LithoLyte and KSPtabs supplements would offer a
more protective role with the gastrointestinal adverse effects.
It must be acknowledged that this is the ﬁrst step toward the
development of over-the-counter alkali therapy for the kidney
stone formation concerning side effects, tolerability, and cost.
However, due to the deﬁciency in the design comprehensive
studies under metabolic regimen using these alternative overthe-counter alkali supplements, must be performed in kidney
stone forming population to overcome the limitation of this
study. I feel until that time the AUA guidelines 4 recommended
potassium citrate as the primary alkali therapy for kidney stone
formers must be followed by urologists and nephrologists
involved in management and care of this population.

Sakhaee Khashayar, Charles and Jane Pak Center of
Mineral Metabolism and Clinical Research Department of
Internal Medicine, University of Texas Southwestern
Medical Center Dallas, Texas
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Reply by authors:

We appreciate the thoughtful critique of this manuscript by the
author of the editorial. The purpose of this study was not to
show that these over-the-counter alternatives are as effective as
potassium citrate; we did not have a control group on potassium
citrate. Rather, we tested whether these commonly used alkali
supplements actually change urine parameters in healthy subjects.
Online shopping has empowered patients to look for alternative therapies due to potassium citrate cost, side effects, pill size,
and/or desire for a “natural” approach. While dozens of options
exist, the endourology community needs to study these therapies
so that patients are able to choose effective options based on science, not star ratings and online reviews.
Studying alkali alternatives in a small sample size is not novel.
Twelve patients were given 2L of lemonade with signiﬁcant
improvements in urine citrate,1 which continues to be 1 of the
most common adjunctive therapies used. Thirteen subjects on a
metabolic diet were studied to show that orange juice is a superior alkali compared to lemonade.2 And 8 patients demonstrated
the beneﬁt of coconut water consumption due to the alkali effect
of high malate intake.3 Certainly, our 10-subject study with varied alkali loads between supplements on self-controlled diets is a
limitation. While we were not directly comparing 1 supplement
to the other, we chose to maintain a similar dosing frequency for
consistency despite the alkali loads. In addition, given the lower
potassium citrate content of these preparations compared to
pure potassium citrate, we might not see a robust urinary potassium response. Any patient started on alkali therapy should be
monitored with 24 hour urine studies to ensure efﬁcacy. We will
further study 24 hour urine parameters in an at-risk study population.
We are indebted to Dr. Sakhaee et al. at the Charles and Jane
Pak Center for Mineral Metabolism and Clinical Research at
UT Southwestern, whose work on nephrolithiasis pathophysiology and prevention is the foundation for much of what we do.
Products continue to be developed for kidney stone prevention,
many within our own community. As stewards of preventative
therapy, we need to study and be critical of these options in
order to better guide our patients.
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